Caliway Biopharmaceuticals (6919) Q3 2025 earnings summary

Executive summary

• Focused on new drug development for aesthetic medicine and chronic inflammation, with shares listed on TWSE in October 2024.

• Consolidated financials reviewed for the nine months ended September 30, 2025 and 2024.

Financial highlights

• Operating revenue for the nine months ended September 30, 2025 was $25,627 thousand, down from $35,071 thousand year-over-year.

• Net loss for the nine months ended September 30, 2025 was $432,108 thousand, compared to $532,692 thousand in the prior year period.

• Gross profit margin remained stable at 68% for the nine months ended September 30, 2025.

• Basic loss per share for the nine months ended September 30, 2025 was $(0.28), improved from $(0.38) year-over-year.

• Cash and cash equivalents at September 30, 2025 were $3,001,639 thousand, down from $6,901,490 thousand at December 31, 2024.

Outlook and guidance

• Adoption of new IFRS standards in 2026 and 2028 is not expected to have significant impact.

• Management continues to evaluate the impact of future IFRS changes, with disclosures to follow upon completion.